The upgrade from Neutral to Buy indicates a positive outlook for Rhythm Pharmaceuticals. The raised price target from $22 to $27 suggests that the analyst believes the stock has potential for significant growth. This could lead to increased investor interest and a potential rise in stock price in the short term.